Amisyn _ STXBP6 Antibody
- Known as:
- Amisyn _ STXBP6 Antibody
- Catalog number:
- AF1059a
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Abgen
- Gene target:
- Amisyn _ STXBP6 Antibody
Related genes to: Amisyn _ STXBP6 Antibody
- Gene:
- STXBP6 NIH gene
- Name:
- syntaxin binding protein 6
- Previous symbol:
- -
- Synonyms:
- amisyn, HSPC156
- Chromosome:
- 14q11.2
- Locus Type:
- gene with protein product
- Date approved:
- 2002-11-12
- Date modifiied:
- 2016-01-19
Related products to: Amisyn _ STXBP6 Antibody
Related articles to: Amisyn _ STXBP6 Antibody
- Circular RNAs (circRNAs) are emerging as potential biomarkers due to their role in gene regulation. We explored whether specific circRNAs could serve as biomarkers for cervical cancer screening by distinguishing between different stages of cervical disease. - Source: PubMed
Publication date: 2026/02/19
Zhong MichaelPeitz JosephineNewman MichelleYussuf SamiatuAdebamowo Clement AChawla Kiranpreet KCarvajal Diana NPlotkin Amy JStaats Paul NAdebamowo Sally N - Ovarian cancer (OC) is the primary cause of mortality related to cancers of the female reproductive system. Early diagnosis remains a major challenge, contributing to a high mortality rate and underscoring an urgent need for novel diagnostic approaches and effective therapeutic strategies. Here, we identify Syntaxin binding protein 6 (STXBP6) as a previously unrecognized oncogenic driver in OC. We demonstrate that STXBP6 expression is markedly elevated in OC tissues and cells and that it promotes OC growth and metastasis both in vitro and in vivo. RNA sequencing revealed that STXBP6 reprograms lipid metabolism, and mechanistic studies confirmed that it enhances OC progression through fatty acid oxidation (FAO). Moreover, activation of the PI3K/AKT signaling pathway was essential for STXBP6-driven FAO and malignant phenotypes. These findings uncover a novel STXBP6/PI3K/AKT axis, providing new insights into OC metabolic reprogramming and potential therapeutic targets. - Source: PubMed
Publication date: 2025/10/29
Wang MinXu HangLi QinkeJin FengzhenZhang SiyingWang JinlongYang Zhu - To explore the immunological underpinnings and prognostic potential of gene expression profiles in bladder cancer through comprehensive analyses of The Cancer Genome Atlas (TCGA) data. We used the TCGA data to identify differentially expressed genes (DEGs) and performed enrichment analysis to reveal the related biological pathways. Meanwhile, the least absolute shrinkage and selection operator (LASSO) algorithm was adopted to develop a prognostic model. Then we evaluated the performance of the model in both TCGA and GSE13507 datasets. Furthermore, we conducted a comprehensive investigation on the feature genes utilized in model construction, encompassing both gene expression profiling and survival analysis. Finally, immune infiltration analysis and drug sensitivity analysis were applied to elucidate the immunological basis of the disease and provide potential therapeutic strategies. We identified a total of 837 DEGs, with a focus on immune-related genes. Using the LASSO algorithm, we developed a prognostic model incorporating seven key genes-NXPH4, FAM110B, GPC2, STXBP6, CYP27B1, GARNL3, and PTGER3-which demonstrated strong predictive accuracy in both TCGA and GSE13507 datasets. Moreover, immune infiltration analysis revealed a higher abundance of M0 and M2 macrophages in high-risk patients, suggesting that macrophage polarization could be a potential therapeutic target to modulate the immune microenvironment. Drug sensitivity analysis further suggested that high-risk patients exhibit differential responses to several chemotherapy agents, with potential therapeutic implications. This study constructed an effective prognostic model, providing new insights and potential therapeutic targets for the personalized treatment of bladder cancer, which needs further validation. - Source: PubMed
Publication date: 2025/06/26
Zhou YeZhang HengyanYan HeguoHan PingxingLiu Yangwen - The outbreak of coronavirus disease 2019 (COVID-19) has resulted in a remarkable threat to global public health over the past few years. Despite the tremendous studies of COVID-19 ongoing, few have focused on the viral impact on the ocular surface. As one of the most common inflammatory diseases of the ocular surface, pterygium could be triggered under multiple environmental exposures. In the present work, we aimed at investigating the potential interactions between pterygium and COVID-19. Based on bioinformatic tools, we compared databases of COVID-19 and pterygium and screened for common differentially expressed genes (DEGs). Multifactor regulatory network and co-expression network of the common DEGs were analyzed. In vitro experiments, including siRNA knockdown using human conjunctival fibroblasts (HConFs) confirmed the bioinformatics results. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis implied that immune response was associated with COVID-19-induced ocular events. We then identified five common DEGs, including ERP27, SYTL5, STXBP6, EXTL1 and DIO2, which was further validated by in vitro experiments. Three hub genes were further extracted which included SYTL5, STXBP6 and ERP27 through protein-protein interactions (PPI) network. Furthermore, we illustrated a regulatory network consisting of eight transcription factors (STAT6B, GATA1, POU2F2, PGR, RBPJ, STAT3, CRTC1 and HMGA1) and one microRNA (hsa-miR-384). Overall, we investigated the common link between SARS-CoV-2 and pterygium in the modulation of gene profiles on the ocular surface. Our study proposed a novel insight into the common pathogenic mechanisms between COVID-19 and pterygium, which are associated with immune dysregulation and pathological proliferation, indicating a viral impact on pterygium susceptibility. This innovative perspective may enable a more comprehensive understanding and advance towards improved clinical prevention and treatment. - Source: PubMed
Publication date: 2025/07/14
Zhou TianyiCai XueyaoShi WenjunDing XiaCai Yuchen - To investigate the clinical value and mechanism of action of long non-coding RNA PRKCQ-AS1 for lung adenocarcinoma (LUAD) progression. - Source: PubMed
Publication date: 2025/07/01
Liu LinglingLiu XiaofenWu XiaojiaoFang HangShi JingjingJiang Wei